Tagged with Innovation,

pharma The General Manager of Boehringer Ingelheim South Africa talks about changes that are required to the healthcare system, with far more government/private partnerships, helping to unlock the country´s potential, why South Africa acts as a springboard for many companies looking to develop their footprint in the region, making it the…

pharma Thomas Würdinger, winner of the 2014 Galenus prize, discusses his research team’s efforts to developing new treatment options and protocols for brain cancers, and the need for greater attention and investment in brain cancer treatment development, an area he identifies as the greatest unmet medical need in the field of…

pharma  David Lenihan, CEO of Ponce Health Sciences University (PHSU), and Kenira Thompson, president of the Ponce Research Institute, highlight the institution’s pioneering efforts in creating cultural competency for medical graduates and increasing investments in clinical research from the US for large-scale trials. What are your perceptions of Puerto Rico’s research…

pharma ”The Mon Trésor Smart City will cater to the business needs of the global healthcare and life sciences sector as no other smart city can.” The Head of Property Development of Omnicane Mauritius explains why while explaining the significance of the project for the sustainable development of the Mauritian economy. There…

pharma Agustín Rullán, Dean of the College of Engineering at UPR Mayagüez, discusses the institution’s latest developments in engineering courses and their applicability in a practical industrial setting for students to jumpstart their professional careers. As a leading engineering college with 4,300 undergraduates and 400 graduates, the College plays a very…

pharma Jörg Buck, the Executive Director of the Italian-German Chamber of Commerce discusses the close trade relationship which ties the two countries together, how the business environment in Italy is evolving today and the need to keep the momentum in the economic recovery. To start off, having joined the chamber recently,…

Pharma The CEO of BioTech Africa, Jason Lurie, evaluates the domestic and global landscape for diagnostic recombinant proteins, and highlights other developmental streams that have helped diversify the company’s portfolio. He also illustrates the underlying aspirations in targeting this market niche, while depicting the distinct set of hurdles faced from the…

Pharma The owner of Altis Biologics, Nick Duneas, illustrates the significance of the company’s flagship product, the Altis Osteogenic Bone Matrix (OBM) and how the company plans to commercialize the injectable bone graft substitute on a domestic and international scale moving forward. He also highlights how the Innovation Prize for Africa has…

Pharma The Netherlands Cancer Institute (NKI) has been at the international forefront of cancer research and treatment for more than 100 years. The director of research discusses the fields and collaborations the institute is currently focusing on and why funding to (blue-sky) research should be seen as an investment. What were…

pharma The Director of the CNCR and the person in charge of the industrial sector, talk about the fragmented nature of French clinical research funding, why when it comes to boosting France’s attractiveness as a clinical research destination, funding is the number one issue for hospitals and reveals how the number…

France PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of access to innovation for patients in one of the world’s fastest-growing regions. You were appointed President of Novartis Latin America…

France The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership in the past few years, her perspective on market access in France and the challenges and opportunities she has faced…